179 related articles for article (PubMed ID: 20184766)
21. Dried blood spots for viral load monitoring in Malawi: feasible and effective.
Rutstein SE; Hosseinipour MC; Kamwendo D; Soko A; Mkandawire M; Biddle AK; Miller WC; Weinberger M; Wheeler SB; Sarr A; Gupta S; Chimbwandira F; Mwenda R; Kamiza S; Hoffman I; Mataya R
PLoS One; 2015; 10(4):e0124748. PubMed ID: 25898365
[TBL] [Abstract][Full Text] [Related]
22. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.
Leierer G; Grabmeier-Pfistershammer K; Steuer A; Geit M; Sarcletti M; Haas B; Kanatschnig M; Rappold M; Zangerle R; Ledergerber B; Taylor N;
PLoS One; 2015; 10(11):e0142923. PubMed ID: 26566025
[TBL] [Abstract][Full Text] [Related]
23. Point-of-care viral load monitoring: outcomes from a decentralized HIV programme in Malawi.
Nicholas S; Poulet E; Wolters L; Wapling J; Rakesh A; Amoros I; Szumilin E; Gueguen M; Schramm B
J Int AIDS Soc; 2019 Aug; 22(8):e25387. PubMed ID: 31441242
[TBL] [Abstract][Full Text] [Related]
24. The viral load monitoring cascade in a resource-limited setting: A prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho.
Glass TR; Motaboli L; Nsakala B; Lerotholi M; Vanobberghen F; Amstutz A; Lejone TI; Muhairwe J; Klimkait T; Labhardt ND
PLoS One; 2019; 14(8):e0220337. PubMed ID: 31461455
[TBL] [Abstract][Full Text] [Related]
25. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
[TBL] [Abstract][Full Text] [Related]
26. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
Shoko C; Chikobvu D; Bessong PO
S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
[TBL] [Abstract][Full Text] [Related]
27. Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.
Darcis G; Maes N; Pasternak AO; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Elmoussaoui M; Fombellida K; Vaira D; Moutschen M
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818822
[TBL] [Abstract][Full Text] [Related]
28. Challenges with targeted viral load testing for medical inpatients at Queen Elizabeth Central Hospital in Blantyre, Malawi.
Craik A; Patel P; Patel P; Mallewa J; Malisita K; Bitilinyu-Bangoh J; van Oosterhout JJ; Kelly C
Malawi Med J; 2016 Dec; 28(4):179-181. PubMed ID: 28321282
[TBL] [Abstract][Full Text] [Related]
29. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
30. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
Antiretroviral Therapy Cohort Collaboration (ART-CC)
Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
[TBL] [Abstract][Full Text] [Related]
31. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
[TBL] [Abstract][Full Text] [Related]
32. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
33. Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada.
Benoit AC; Younger J; Beaver K; Jackson R; Loutfy M; Masching R; Nobis T; Nowgesic E; O'Brien-Teengs D; Whitebird W; Zoccole A; Hull M; Jaworsky D; Benson E; Rachlis A; Rourke SB; Burchell AN; Cooper C; Hogg RS; Klein MB; Machouf N; Montaner JSG; Tsoukas C; Raboud J
Can J Public Health; 2017 Jun; 108(2):e169-e175. PubMed ID: 28621653
[TBL] [Abstract][Full Text] [Related]
34. Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study.
Solomon SS; Mehta SH; McFall AM; Srikrishnan AK; Saravanan S; Laeyendecker O; Balakrishnan P; Celentano DD; Solomon S; Lucas GM
Lancet HIV; 2016 Apr; 3(4):e183-90. PubMed ID: 27036994
[TBL] [Abstract][Full Text] [Related]
35. Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study.
Gill MM; Hoffman HJ; Bobrow EA; Mugwaneza P; Ndatimana D; Ndayisaba GF; Baribwira C; Guay L; Asiimwe A
PLoS One; 2016; 11(12):e0168671. PubMed ID: 28006001
[TBL] [Abstract][Full Text] [Related]
36. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
37. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study.
Lampe FC; Porter K; Kaldor J; Law M; Kinloch-de Loes S; Phillips AN;
Antivir Ther; 2007; 12(2):189-93. PubMed ID: 17503661
[TBL] [Abstract][Full Text] [Related]
38. Virological suppression among gay, bisexual, and other men who have sex with men living with HIV in Vancouver, Canada: A longitudinal cohort study from 2012-2017.
Armstrong HL; Gitelman J; Cui Z; Bacani N; Sereda P; Lachowsky NJ; Card KG; Sang JM; Raymond HF; Montaner J; Hall D; Howard T; Hull M; Hogg RS; Roth EA; Moore DM
PLoS One; 2022; 17(10):e0276596. PubMed ID: 36269767
[TBL] [Abstract][Full Text] [Related]
39. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
[TBL] [Abstract][Full Text] [Related]
40. Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting.
Loh J; Kennedy MC; Wood E; Kerr T; Marshall B; Parashar S; Montaner J; Milloy MJ
AIDS Care; 2016 Nov; 28(11):1448-54. PubMed ID: 27248328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
